⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879074 | 1.00 | — | — | |
| SCHEMBL152150 | 1.00 | — | — | |
| SCHEMBL9203898 | 1.00 | — | — | |
| SCHEMBL2724423 | 1.00 | — | — | |
| SCHEMBL764547 | 1.00 | — | — | |
| SCHEMBL532330 | 1.00 | — | — | |
| SCHEMBL1870963 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL1922314 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL3442349 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL15568382 | 0.97 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 828 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4656656-A2 | COMBINATION HBV THERAPY | Humabs BioMed SA (CH) | 2025-12-03 | — | — | EP | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4285929-B1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2025-10-08 | — | — | EP | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| EP-3647424-B1 | HEPATITIS B VIRUS (HBV) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2025-09-10 | — | — | EP | claimed |
| EP-3366775-B2 | MODIFIED RNAI AGENTS | ALNYLAM PHARMACEUTICALS INC (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4526338-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4526339-A2 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | VIR Biotechnology, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2022182294-A1 | METHODS FOR LIGATION OF (POLY)PEPTIDES AND OLIGONUCLEOTIDES | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-09-01 | — | — | WO | claimed |
| EP-4007812-A1 | SERPIN FAMILY F MEMBER 2 (SERPINF2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2022-06-08 | — | — | EP | claimed |
| US-11324820-B2 | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-05-10 | — | — | US | claimed |
| US-11286486-B2 | Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-29 | — | — | US | claimed |
| EP-3969588-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | VIR Biotechnology, Inc. (US) | 2022-03-23 | — | — | EP | claimed |
| CN-108368507-B | iRNA compositions of programmed cell death 1 ligand 1(PD-L1) and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-03-22 | — | — | CN | claimed |
| US-20220071965-A1 | Pharmaceutical Compositions and Methods Comprising A Combination of a Benzoxazole Transthyretin Stabilizer and an Additional Therapeutic Agent | PFIZER INC. (US) | 2022-03-10 | — | — | US | claimed |
| US-11261447-B2 | Methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-03-01 | — | — | US | claimed |
| CN-114126628-A | Compositions and methods for treating Hepatitis B Virus (HBV) infection | 维尔生物科技有限公司 | 2022-03-01 | — | — | CN | claimed |
| US-20220056110-A1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2022-02-24 | — | — | US | claimed |